Does insurance cover Zepbound for sleep apnea?

Zepbound’s December 2024 OSA indication is a separate labeled use from weight loss. Medicare Part D still excludes drugs when they are used for weight loss. That exclusion does not automatically block an OSA prescription, and it does not mean “Medicare covers Zepbound.” Coverage is plan-specific, usually with prior authorization. Ohio commercial contracts were not verified for this article.

Does Medicare cover Zepbound?

Do not write or repeat the sentence “Medicare covers Zepbound.” Original Medicare Part B does not pay for this weekly injection as a clinic-administered sleep-apnea service in the way it pays for a sleep study. The relevant benefit, if any, is Medicare Part D (or the drug benefit inside a Medicare Advantage plan). Part D is a private formulary wrapped in federal rules.

The Social Security Act’s Part D definition of a covered drug, 42 U.S.C. § 1395w-102(e)(2)(A) (SSA § 1860D-2(e)(2)(A)), incorporates the Medicaid rebate statute’s list of excludable agents. That list, 42 U.S.C. § 1396r-8(d)(2)(A), begins with “Agents when used for anorexia, weight loss, or weight gain.” The phrase that matters is “when used for.” The same molecule can be a covered Part D drug for one labeled use and excluded for another. Obesity-only prescribing hits the exclusion. An FDA-labeled use that is not weight loss can sit outside that clause, if the plan puts the drug on formulary for that use and if prior authorization is satisfied.

Zepbound’s USPI has two bullets: weight reduction, and moderate to severe OSA in adults with obesity, both with diet and activity. A prescription written “for weight loss” is the excluded use even if the patient also snores. A prescription written for the OSA indication, with a sleep study in the chart, is the use Part D plans may consider. “May” is the correct verb. There is no national coverage determination that every Part D plan must list tirzepatide for OSA. Formularies differ. Tiers differ. Some plans will deny. An appeal or a formulary exception is a plan process, not a federal guarantee.

Medicare Advantage medical benefits and Part D pharmacy benefits are easy to confuse. The implant LCD for Inspire is a medical-benefit document. Zepbound is a pharmacy-benefit question. Calling the medical prior-auth line about a weekly pen will waste a week.

What do commercial plans usually want?

Prior authorization is the default, not the exception. A typical OSA-indication packet, based on how these drugs are managed rather than on an Ohio Blue PDF we opened today, includes:

• A sleep-study report showing moderate to severe OSA (trials used AHI of 15 or higher; the labeled indication says “moderate to severe” in adults with obesity).
• BMI in the obesity range (trials used 30 kg/m² or higher; section 1 of the USPI says “adults with obesity”).
• The diagnosis on the prescription matching OSA, not “obesity management,” if the plan carves out anti-obesity agents.
• Documentation that diet and activity are part of the plan, because the label requires them.
• Sometimes evidence about PAP: using it, unable to use it, or unwilling. The USPI does not require PAP failure for the OSA indication. A given payer might still ask. That extra ask is UNVERIFIED for named Ohio plans.

UnitedHealthcare, Aetna, Cigna, Anthem Blue Cross Blue Shield, Medical Mutual, UMR, Oscar, MediGold, and Buckeye appear as insurance names associated with this practice’s public materials. Those logos are not a statement that any of them cover Zepbound for OSA this year. Ohio Medicaid status is also UNVERIFIED. TRICARE is UNVERIFIED. Call the number on the back of the card and ask for the tirzepatide / Zepbound medical policy for obstructive sleep apnea, not for “weight-loss shots.”

Can the OSA indication bypass a weight-loss exclusion?

Sometimes, on paper. A plan that excludes anti-obesity drugs may still have a path for the OSA indication because the FDA text is a different bullet. Sometimes the plan’s exclusion is written as “all GLP-1 and GIP/GLP-1 agonists for any use except diabetes,” which would still block Zepbound. You cannot know which sentence you are in without the policy. Do not assume the December 2024 approval rewrote your employer’s carve-out.

If the denial letter cites “weight loss not a covered benefit,” ask whether the claim was coded as obesity or as OSA. Recoding a weight-loss request as OSA without a qualifying sleep study is fraud, not a workaround. Recoding after a real PSG and a real obesity-plus-OSA visit is what the indication is for. The sleep physician’s note should say moderate to severe OSA, adult with obesity, used with diet and activity, and that PAP was addressed. It should not promise that AHI will fall by 25 events because that was a trial mean, not your mean.

People already on Mounjaro for diabetes are on a different labeled product. The Zepbound USPI recommends against coadministration with other tirzepatide products. Insurance will not pay for both. That is a medication-reconciliation problem before it is a PA problem.

What does a paid claim not decide?

It does not decide that you should stop PAP. The USPI is explicit that SURMOUNT-OSA did not study the timing or appropriateness of stopping PAP in people who had been compliant. Study 6 enrolled people on PAP. A pharmacy approval is not a sleep-lab clearance to unplug the machine.

It does not set this practice’s price. List prices, coupon cards, and compounding offers are not Westerville Sleep Center fees. We do not quote a cash price for tirzepatide in this article.

It does not replace follow-up. If the clinical goal is AHI, you need a later study. If the clinical goal is weight, you need a scale and a diet you can actually keep. The label requires both diet and activity alongside the pen.

How should an Ohio patient actually check?

Three phone numbers, in order. First, the pharmacy benefit number on the insurance card: “Is Zepbound on formulary for obstructive sleep apnea, what tier, and what is the PA form?” Second, the dispensing pharmacy: “Do you stock the 2.5 mg starter dose, and will you run a test claim?” Third, this office: (614) 898-9340, so the chart has the sleep study and the BMI before anyone submits PA. Hours are Monday through Friday, 8:00 AM to 5:00 PM, at 450 Alkyre Run Drive, Suite 230, Westerville.

If you are on fee-for-service Medicare, ask specifically about your Part D plan's name (the PDP), not "Medicare." If you are on Medicare Advantage, ask whether the drug is billed under the plan's Part D formulary. If you have a commercial Ohio plan, do not use a national blog's "Anthem covers it" table. Ask for your group's policy.

Starter-dose timing trips people after an approval. The USPI starts everyone at 2.5 mg weekly for four weeks; that strength is initiation only, not OSA maintenance. Maintenance for the OSA indication is 10 mg or 15 mg once weekly. A PA that approves "Zepbound" without naming those maintenance strengths can stall at the pharmacy when the box changes. Ask the plan whether a new authorization is required at each step. That rule is plan-specific and UNVERIFIED for Ohio contracts. Keep PAP going unless a sleep physician, looking at a later study, says otherwise. Pharmacy payment is not a titration protocol and it is not permission to stop the machine.

For the clinical indication and the SURMOUNT-OSA numbers, read the companion article and the Zepbound treatment page. For sleep apnea testing you do not yet have, start there. For general billing questions that are not this drug, see insurance and costs. Bring the denial letter to the visit if you already have one. Do not paste health information into a website form. If the denial cites “weight loss exclusion,” ask the plan in writing whether it applied the OSA indication at all. A weight-loss exclusion that never looked at the sleep-study AHI is a different problem from a PA that looked at AHI and still said no.